Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
NCT03806127 is registered in ClinicalTrials.gov with Urovant Sciences GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
- Lead sponsor
- Urovant Sciences GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2018
- Completion date
- October 6, 2020
- Enrollment
- 222 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.